Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,098 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05221645 | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma(P+R-ICE) | active not recruiting | Phase 2 | 65 | University of SouthamptonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04458610 | Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 |
| clinicaltrials |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 24 | Yale UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05497804 | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | active not recruiting | Phase 2 | 17 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | active not recruiting | Phase 1 / Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06400225 | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06504199 | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma(ZGR) | active not recruiting | Phase 2 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT04263480 | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia(CZAR-1) | active not recruiting | Phase 2 | 99 | Christian BuskeOTHER | 3 | May 12, 2026 | clinicaltrials |
| NCT00871013 | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | active not recruiting | Phase 2 | 160 | University of ArkansasOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04273139 | Ibrutinib + Venetoclax in Untreated WM | active not recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | active not recruiting | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04439110 | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | May 8, 2026 | clinicaltrials |
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | active not recruiting | Phase 2 | 140 | PETHEMA FoundationOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT03322865 | Obinutuzumab in Marginal Zone Lymphoma | active not recruiting | Phase 2 | 56 | Christian BuskeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03474744 | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | active not recruiting | Phase 2 | 36 | Christian BuskeOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04439175 | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04657094 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT04978584 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | active not recruiting | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05490771 | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04546620 | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)(REMoDL-A) | active not recruiting | Phase 2 | 453 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04653246 | Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | active not recruiting | Phase 2 | 52 | Jacob Laubach, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | active not recruiting | Phase 2 | 27 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03863184 | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | active not recruiting | Phase 2 | 37 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05253118 | Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)(SPECTRUM) | active not recruiting | Phase 2 | 28 | Seoul National University HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05507541 | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease(EMN19) | active not recruiting | Phase 2 | 41 | Stichting European Myeloma NetworkNETWORK | 3 | Apr 20, 2026 | clinicaltrials |
| NCT04561492 | Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma(PentiMyelo) | active not recruiting | Phase 2 | 45 | Nantes University HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04939272 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07162181 | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | active not recruiting | Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04189757 | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | active not recruiting | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02420860 | Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02960555 | Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | active not recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 15, 2026source: clinicaltrials